ArticleHuman vaccines & immunotherapeutics2026
Budget impact analysis of bivalent respiratory syncytial virus prefusion F (RSVpreF) maternal vaccination for preventing respiratory syncytial virus in Egyptian infants.
Article in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections (LRTIs) in infants in low- and middle-income countries, and Egypt faces a clinical and economic burden associated with it. This study aimed to estimate the 5 y budget impact of maternal RSV Prefusion F (RSVpreF) vaccination, compared with no vaccination, from the public healthcare payer perspective in Egypt. A deterministic cohort model simulated weekly birth cohorts for five years, assuming a 10% maternal uptake of RSVpreF administered year-round at 24-36 weeks' gestation. Outcomes included RSV-LRTI cases, healthcare use (hospitalizations, emergency department, and outpatient), and RSV-related deaths among infants, with costs reported both in aggregate and as per-member-per-year (PMPY). Deterministic sensitivity analysis (DSA) varied clinical and economic inputs by ±30%. Without vaccination, 425,421 RSV-LRTI events, 1,173 RSV-related deaths, and EGP 1,652.3 million in medical costs were projected over five years among 9,877,775 live births. With 10% maternal vaccination, 16,784 RSV-LRTI events and 69 deaths were averted, yielding medical cost offsets of EGP 95.0 million. Vaccination costs of EGP 8,578.1 million produced an incremental PMPY of EGP 15.92 (USD 0.3) under list-price assumptions. In DSA (±30%), results were most sensitive to vaccine acquisition price, with other parameters exerting smaller effects, and the conclusions remained unchanged. Conclusively, maternal RSVpreF vaccination can reduce RSV burden in Egypt's public sector, and at list price, the program results in a net incremental budget of EGP 15.92 (USD 0.3) PMPY; lower public procurement prices would proportionally reduce the net impact while preserving clinical gains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.